February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
1 citations
,
March 2017 in “European Journal of Cancer Prevention” 24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
1 citations
,
May 1992 in “Pharmacological Research”
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
20 citations
,
January 2004 in “PubMed Central” 5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
September 2002 in “Research Repository (Kingston University London)” Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
19 citations
,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
12 citations
,
March 1995 in “Journal of the American Chemical Society” Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
May 2007 in “Inpharma Weekly”
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
September 2004 in “Inpharma Weekly” 3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
12 citations
,
March 2017 in “Medicinal Chemistry Research” Some curcumin-like compounds can effectively and safely block the enzyme linked to hair loss and other conditions related to male hormones.